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Synthesis and biological evaluation of a kabiramide C fragment 
modified with a WH2 consensus actin-binding motif as potential 
disruptor of the actin cytoskeleton† 
Daniel J. Tetlow,
a
 Steve J. Winder*
b
 and Christophe Aïssa*
a
The F-actin depolymerisation potency of a fragment of kabiramide 
C was increased when modified with a WH2 consensus actin-
binding motif LKKV. Despite its low affinity for actin monomers, a 
shorter  analogous fragment not bearing LKKV was identified as a 
potent inhibitor of actin polymerisation and promoter of its 
depolymerisation, resulting in a loss of actin stress fibres in cells. 
The control of the actin cytoskeleton by actin-binding proteins 
(ABPs) is vital to a large number of fundamental cellular 
processes.
1
 The Wiskott-Aldrich syndrome protein-homology 
domain 2 (WH2) is an actin-binding motif that binds actin 
between its subdomains 1 and 3.
2 
WH2 is widely spread among 
ABPs and a representative example of actin/WH2 complex is 
depicted in Fig. 1a with the WH2 of the missing in metastasis 
protein (MIM, cyan and red cartoon).
3
 In WH2, a key actin-
recognition element consists of two basic residues (usually 
lysine), flanked by two hydrophobic residues.
2,4
 Thus, a typical 
WH2 consensus actin-binding motif is LKKV or LKKT (Fig. 1a, 
red section of the cartoon).
2–4
 Moreover, the actin 
cytoskeleton can be disrupted by several natural products,
5,6
 
among which kabiramide C (1) (Fig. 1b, green tubes),
7
 
aplyronine A and reidispongiolide A are prime examples. These 
marine toxins are structurally related and consist of a well-
conserved aliphatic side chain attached to a macrolactone of 
varying size and structure. The crystal structures of the 1:1 
complexes of these compounds and the actin monomer (G-
actin) show considerable overlap of their binding site on actin 
with those of WH2 in actin/WH2 complexes, as illustrated with 
1 in Fig. 1a.
7,8
 Importantly, previous studies suggest that these 
compounds disrupt the actin cytoskeleton by slowly severing 
actin filaments (F-actin) and capping the shortened filament 
thus formed at their so-called barbed end.
8
 In addition, the 
sub-nanomolar affinity of these natural toxins for G-actin 
suggests that the elongation of the filaments is also prevented 
by the incorporation of a G-actin/toxin complex at the barbed 
end of the filaments.
8
 Remarkably, when truncated from the 
macrolactone ring, the lateral chain of aplyronine A and 
analogues thereof can still promote the depolymerisation of F-
actin but with at least a ten-fold reduced potency as compared 
to the natural product.
9
 Similarly, analogues of the lateral 
chain of reidispongiolide A, whereby the macrolactone ring is 
replaced with small apolar groups to enhance the hydrophobic 
interactions with actin, still display a sub-micromolar affinity 
for G-actin and are reported to sever F-actin.
10 
 
Fig. 1 (a) Superimposition of actin/WH2 of MIM (1:1) complex (PDB: 2D1K, cyan and 
red cartoon) and actin/kabiramide C (1:1) complex (PDB: 1QZ5, green tubes). (b) 
Structure of kabiramide C (1). (c) Structure of hybrids 2 designed from the truncated 
side chain of 1 and the key actin-binding tetrapeptide LKKV. 
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Scheme 1 Synthesis of compounds. (a) 3a–c, Dess-Martin periodinane (1.85 equiv), 
NaHCO3 (2 equiv), CH2Cl2, rt, 0.25h; (b) i) 4 (1 equiv), Ba(OH)2 (1.1 equiv), THF, 0.5h 
then ii) aldehyde obtained from 3a–c (1 equiv), THF/water (40:1), rt, 1h; (c) (CuHPPh3)6 
(0.33 equiv), water (10 equiv), toluene, rt, 1h; (d) CuI (0.2 equiv), 1,2-trans-
cyclohexyldiamine (0.4 equiv), K3PO4 (2 equiv), MeNCHO (10 equiv), 1,4-dioxane, 80 °C, 
16h; (d) AgNO3 (4 equiv), THF/EtOH/water/2,6-lutidine (1:1:1:0.1), rt, 48h; (e) CuSO4 
(0.1 equiv), sodium L-ascorbate (0.2 equiv), 8 or 9, t-BuOH, 35 °C, 48h. 
In contrast to the strategy previously followed with the 
modified fragments of reidispongiolide A
10
 and in view of the 
proximity of the WH2 consensus actin-binding motifs and 1 
when in complex with G-actin (Fig. 1a),
3,7
 we hypothesised that 
replacing the macrolactone moiety of 1 with the key actin-
binding tetrapeptide LKKV in compounds 2 (Fig. 1c) would 
deliver hybrids that could trigger similar effects on the actin 
cytoskeleton as compared to 1. According to this design, both 
actin-binding sections of 2 would be tethered by a chain of 
adjustable length (n = 5–7) and a triazole moiety that would 
replace one of the oxazole rings of 1 (highlighted in grey). We 
anticipated that this design could serve as a new basis for the 
future development of molecular tools to study the actin 
cytoskeleton, or drugs to fight diseases (e.g. cancer, viral 
infection, intraocular pressure and outflow) by targeting 
actin.
11 
Our approach towards hybrids 2 is illustrated in Scheme 1. 
Horner-Wadsworth-Emmons olefination between advanced 
fragments 3 and 4
12,13
 gave 5. The reduction of the carbon-
carbon double bond thus formed using Stryker’s reagent
14
 
afforded intermediate 6, with partial desilylation of the 
terminal alkyne (4%). The crude material was used without 
further purification in the next step. The N-methyl formamide 
moiety was installed using a copper-catalysed amidation 
reaction,
9b,15
 and those basic conditions caused partial 
isomerisation at C(6).
16,17
 The diastereomers were not 
separated and the synthesis was pursued nonetheless, as we 
assumed that the ratio of diastereomers would not prevent a 
meaningful evaluation of our hypothesis about the biological 
activity of the final compounds. Thus, cleavage of the 
trimethylsilyl group using AgNO3
18
 gave terminal alkyne 7a. 
Attempts of the same cleavage using other conditions such as 
K2CO3 in MeOH or tetrabutylammonium fluoride in THF were 
unsuccessful and led to either incomplete reaction or 
decomposition, respectively. Analogues 7b and 7c were 
prepared in the same fashion, whereby uncontrolled 
desilylation of the triple bond (6b and 6c, 12%) during the 
Stryker reduction and epimerisation at C(6) during the 
amidation reaction were also observed. Although the copper-
catalysed formation of the triazole 2 using alkyne 7a and azide 
8 initially enabled us to obtain 10 has free bases,
19
 we noticed 
a relatively rapid decomposition upon storage. Although the 
products of this decomposition were not identified, we 
suspected that it was linked to the presence of the free 
primary amino groups on the side chains of the two lysine 
residues. Accordingly, we modified the work-up procedure of 
the copper-catalysed 1,3-dipolar addition between 7a and 8 in 
order to isolate 10 as a bis-TFA salt. In order to assess whether 
a putative enhancement of actin-binding properties could be 
attributed to the specific tetrapeptide LKKV, the analogous 
control substrate 11 was prepared from 7a and 9, whereby the 
LKKV fragment was replaced with LAKV. Finally, although we 
initially intended to prepare analogues of 10 from 7b and 7c, 
the results from the initial comparison of the affinity for G-
actin of 7a and 10 did not encourage us to pursue this 
endeavour. 
Thus, a rapid comparison of the G-actin binding properties of 
7a, 10 and 11 was conducted by scanning the fluorescence 
intensity of a 1 µM solution of Prodan-G-actin in the absence 
or presence of 25 µM solutions of the compounds (Fig. 2).
10,20
 
Contrary to our initial hypothesis that modifying 7a with the 
LKKV fragment would increase the affinity of 10 for G-actin, 
the scan did not reveal any evidence of such effect. In contrast, 
a minor increase of affinity was observed for control 
compound 11 which bears the LAKV fragment. Moreover, 
shortening the aliphatic chain in 7a–7c led to compounds with 
increasingly lower affinity for G-actin. 
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Fig. 2 Fluorescence emission spectra of 1 µM Prodan-G-actin in the presence of 25 µM 
compounds 7a–7c, 10, and 11. 
Table 1 Potency of compounds 7a–c, 10 and 11 in regard to the inhibition of G-actin 
polymerisation (A), promotion of F-actin depolymerisation (B) and to the disruption of 
actin cytoskeleton in rat fibroblast cells after 2h (C) and 24h (D)
a
 
Compound Ab Bb C D 
7a 10 (-) 5 (+) ±d 20 
7b 1 (+) 5 (+) 20 20 
7c 1 (-) 5 (+) ±d 0.8 
10 10 (+) 1.5 (+) 20 ±d 
11 ±c 5 (+) 20 ±d 
a Minimal concentration (µM) of compound for which a significant effect was 
observed. b Inhibiting and promoting effects are indicated by a minus and plus 
sign, respectively. c No effect at 10 µM. d No effect at 20 µM. 
 
Fig. 3 Effect of 7c on the actin cytoskeleton in REF52 rat embryo fibroblast cells 24h 
after they have been treated with 0.8–20 µM solutions of the compound. 
The potency of all compounds was nevertheless evaluated in 
G-actin polymerisation
21
 and F-actin depolymerisation assays
22
 
as well as whole cell assays.
23
 In the polymerisation assay of 2 
µM pyrenyl G-actin, the initial rates of polymerisation were 
calculated for compounds in the initial linear phase of 
polymerisation up to 20 minutes. The minimum concentration 
that reduced the polymerisation rate by 10% compared to 
DMSO control was deemed significant. The quantification of 
the depolymerisation assay was performed by measuring the 
amount of actin in the supernatant obtained after incubation 
of 6 µM F-actin with 7a–c, 10, and 11. A compound was 
deemed to have a significant effect at a concentration that 
resulted in 5% of actin in the supernatant fraction whereas 
between 1 and 2% of actin was in the supernatant fraction 
when F-actin was incubated with DMSO only. The results of 
those assays are summarised in Table 1. They demonstrated 
that despite its low affinity for G-actin 7c is a strong inhibitor 
of G-actin polymerisation whilst it also promotes the 
depolymerisation of F-actin. Treating REF52 rat embryo 
fibroblast cells with compound 7c led to a concentration-
dependent loss of actin stress fibres and actin stress fibre 
organisation (Fig. 3). Compared to DMSO alone, 800 nM 7c 
caused an increased accumulation of disorganised F-actin 
clouds in the perinuclear region, with a progressive loss of 
stress fibres and stress fibre organisation with increased 
concentrations up to 20 µM. Furthermore, the numbers of 
cells remaining attached to the culture dish was also reduced 
as the concentration of 7c increased, probably as a 
consequence of the loss of stress fibre-mediated cell adhesion 
contacts to the substratum. At 20 µM 7c, in any remaining 
adherent cells, F-actin was mostly concentrated in dense 
accumulations at the cell periphery adjacent to other cells. 
Among compounds 7a–7c, 7c is the most potent inhibitor of G-
actin polymerisation and the most potent promoter of F-actin 
depolymerisation (Table 1). Moreover, attaching the LKKV 
fragment to the polypropionate chain of 7a increased the 
potency of 10 to act as promoter of F-actin depolymerisation. 
This effect appears to be attributable to the LKKV fragment as 
replacing even only one of the two lysine residues with a non-
basic residue (11, Table 1) led to a complete loss of potency in 
all assays. However, both 10 and 11 failed to elicit any 
significant effects in whole-cell assays, which might be due to 
issues of cell penetration. 
In conclusion, and contrary to our initial hypothesis, modifying 
a simplified side chain of kabiramide C with a WH2 actin-
binding motif does not enhance the affinity of the compound 
thus obtained for G-actin. However, the F-actin 
depolymerisation potency is increased by this modification and 
this effect appears to be specific to the LKKV fragment. 
Moreover, the remarkable effects observed for 7c in the 
assays described above cannot be explained by the 
sequestration of actin monomers due to its low of affinity for 
G-actin, in contrast to the modified side chains of 
reidispongiolide A that exhibit a remarkable sub-micromolar 
affinity for G-actin.
10b
 Further investigations are required to 
delineate more precisely the mechanism of action of this 
compound. 
We are grateful to the Leverhulme Trust (research grant RPG-
198) for financial support and to Dr Neil Berry for his help 
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Notes and references 
1 (a) C. G. dos Remedios, D. Chhabra, M. Kekic, I. V. Dedova, 
M. Tsubakihara, D. A. Berry and N. J. Nosworthy, Physiol. 
Rev. 2003, 83, 433. (b) V. O. Paavilainen, E. Bertling, S. Falck 
and P. Lappalainen, Trends. Cell. Biol., 2004, 14, 386. (c) R. 
COMMUNICATION Journal Name 
4 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
Dominguez, Trends Biochem. Sci., 2004, 29, 572. (d) S. J. 
Winder and K. R. Ayscough, J. Cell Sci., 2005, 118, 651. 
2 D. Chereau, F. Kerff, P. Graceffa, Z. Grabarek, K. Langsetmo 
and R. Dominguez, Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 
16644. 
3 S. H. Lee, F. Kerff, D. Chereau, F. Ferron, A. Klug and R. 
Dominguez, Structure, 2007, 15, 145. 
4 (a) E. Paunola, P. K. Mattila, P. Lappalainen, FEBS Lett., 2002, 
513, 92. (b) B. Qualmann, M. K. Kessels, Trends Cell. Biol., 
2009, 19, 276. 
5 (a) K.-S. Yeung and I. Paterson, Angew. Chem. Int. Ed., 2002, 
41, 4632. (b) J. S. Allingham, V. A. Klenchin and I. Rayment, 
Cell. Mol. Life. Sci., 2006, 63, 2119. 
6 For selected examples not covered in references 5, see: (a) 
A. V. Statsuk, R. Bai, J. L. Baryza, V. A. Verma, E. Hamel, P. A. 
Wender and S. A. Kozmin, Nature Chem. Biol., 2005, 1, 383. 
(b) A. Fürstner, C. Nevado, M. Waser, M. Tremblay, C. 
Chevrier, F. Teplý, C. Aïssa, E. Moulin and O. Müller, J. Am. 
Chem. Soc., 2007, 129, 9150. (c) R. Tannert, L.-G. Milroy, B. 
Ellinger, T.-S. Hu, H.-D. Arndt and H. Walmann, J. Am. Chem. 
Soc., 2010, 132, 3063. (d) D. Herkommer, S. Dreisigacker, G. 
Sergeev, F. Sasse, H. Gohlke and Dirk Menche, 
ChemMedChem, 2015, 10, 470. 
7 V. A. Klenchin, J. S. Allingham, R. King, J. Tanaka, G. Marriott 
and I. Rayment, Nature Struct. Biol., 2003, 10, 1058. 
8 (a) J. Tanaka, Y. Yan, J. Choi, J. Bai, V. A. Klenchin, I. Rayment 
and G. Marriott, Proc. Natl. Acad. Sci. U.S.A., 2003, 100, 
13851; (b) J. S. Allingham, A. Zampella A, M. V. D’Auria and I. 
Rayment, Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 14527; (c) 
K. Hirata, S. Muraoka, K. Suenaga, T. Kuroda, K. Kato, H. 
Tanaka, M. Yamamoto, M. Takata, K. Yamada and H. Kigoshi, 
J. Mol. Biol., 2006, 356, 945. 
9 (a) H. Kigoshi, K. Suenaga, M. Takagi, A. Akao, K. Kanematsu, 
N. Kamei, Y. Okugawa and K. Yamada, Tetrahedron, 2002, 58, 
1075; (b) K. Kitamura, T. Teruya, T. Kuroda, H. Kigoshi and K 
Suenaga, Bioorg. Med. Chem. Lett., 2009, 19, 1896. 
10 (a) R. D. Perrins, G. Cecere, I. Paterson and G. Marriott, 
Chem. Biol., 2008, 15, 287; (b) J. H. Pereira, C. Petchprayoon, 
A. C. Hoepker, N. W. Moriarty, S. J. Fink, G. Cecere, I. 
Paterson, P. D. Adams and G. Marriott, ChemMedChem, 
2014, 9, 2286. 
11 (a) I. Spector, F. Braet, N. V. Shochet and M. R. Bubb, 
Microsc. Res. Techniq., 1999, 47, 18. (b) F. Braet, L. Soon, K. 
Vekemans, P. Thordarson and I. Spector Protein Reviews, ed. 
C. G. dos Remedios and D. Chhabra, Springer, New York, 
2008, 8, 37. 
12 See the supporting information for details of the preparation 
of intermediates 3 and 4. 
13 (a) I. Paterson, K.-S. Yeung and J. B. Smaill, Synlett, 1993, 
774. (b) S. K. Chattopadhyay, G. Pattenden, Tetrahedron 
Lett., 1995, 36, 5271; (c) I. Paterson, K.-S. Yeung, C. Watson, 
R. A. Ward and P. A. Wallace, Tetrahedron, 1998, 54, 11935; 
(d) I. Paterson, S. B. Blakey and C. J. Cowden, Tetrahedron 
Lett., 2002, 43, 6005; (e) A. Zampella, V. Sepe, R. D’Orsi, R. 
Bifulco, C. Bassarello, M. V. D’Auria, Tetrahedron: 
Asymmetry, 2003, 14, 1787; (f) T. J. Hoffman, A. Kolleth, J. H. 
Rigby, S. Arseniyadis and J. Cossy, Org. Lett., 2010, 12, 3348. 
14 W. S. Mahoney, D. M. Brestensky and J. M. Stryker, J. Am. 
Chem. Soc., 1988, 110, 291. 
15 A. Klaspars, J. C. Antilla, X. Huang and S. L. Buchwald, J. Am. 
Chem. Soc., 2001, 123, 7727. 
16 M. Ying and W. R. Roush, Tetrahedron, 2011, 67, 10274. 
17 A doublet of quartets is observed for H(6) in 
1
H NMR (7a: J6-5 
= 9.7 Hz and J6-Me = 7.1 Hz, 7b: J6-5 = 9.6 Hz and J6-Me = 7.0 Hz, 
7c: J6-5 = 9.5 Hz and J6-Me = 7.0 Hz). Accordingly, the 
configuration at C(6) for the major diastereomer of 7a–7c, 10 
and 11 is tentatively assumed to be as depicted in Scheme 1 
by comparison with similar compounds. (a) I. Paterson and 
K.-S. Yeung, Tetrahedron Lett., 1993, 34, 5347. (b)  E. Fleury, 
M.-I. Lannou, O. Bistri. F. Sautel, G. Massiot, A. Pancrazi and 
J. Ardisson, J. Org. Chem., 2009, 74, 7034. 
18 E. M. Carreira and J. Du Bois, J. Am. Chem. Soc., 1995, 117, 
8106. 
19 A. Paul A, H. Bittermann and P. Gmeiner, Tetrahedron, 2006, 
62, 8919. 
20 G. Marriott, K. Zechel and T. M. Jovin, Biochemistry, 1988, 
27, 6214. 
21 M. Pfuhl, S. J. Winder and A. Pastore, EMBO J., 1994, 13, 
1782. 
22 S. J. Winder, L. Hemmings, S. K. Maciver, S. J. Bolton, J. M. 
Tinsley, K. E. Davies, D. R. Critchley and J. Kenderick-Jones, J 
Cell Sci., 1995, 108, 63. 
23 Y.-J. Chen, H. J. Spence, J. M. Cameron, T. Jess, J. L. Ilsley and 
S. J. Winder, Biochem J., 2003, 375, 329. 
